Propanc Biopharma Inc (NASDAQ:PPCB) Sees Large Decline in Short Interest

Propanc Biopharma Inc (NASDAQ:PPCB) saw a large decrease in short interest during the month of June. As of June 30th, there was short interest totaling 16,903 shares, a decrease of 95.2% from the June 15th total of 352,559 shares. Approximately 1.0% of the company’s stock are short sold. Based on an average daily trading volume, of 206,327 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Propanc Biopharma Trading Down 9.6%

Propanc Biopharma stock traded down $0.17 during midday trading on Friday, hitting $1.61. The stock had a trading volume of 218,210 shares, compared to its average volume of 3,221,563. The business has a fifty day moving average price of $1.82 and a 200 day moving average price of $4.62. Propanc Biopharma has a 12 month low of $1.30 and a 12 month high of $270.25. The stock has a market cap of $3.67 million, a P/E ratio of -0.07 and a beta of 3.49.

Propanc Biopharma announced that its board has initiated a stock buyback plan on Thursday, June 11th that permits the company to buyback $5.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 162.3% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s management believes its stock is undervalued.

Institutional Trading of Propanc Biopharma

An institutional investor recently bought a new stake in Propanc Biopharma stock. Virtu Financial LLC purchased a new stake in Propanc Biopharma Inc (NASDAQ:PPCB) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned 0.33% of Propanc Biopharma as of its most recent filing with the SEC.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.